Cargando…
Experiences on recruitment and retention of volunteers in the first HIV vaccine trial in Dar es Salam, Tanzania - the phase I/II HIVIS 03 trial
BACKGROUND: Eventual control of HIV/AIDS is believed to be ultimately dependent on a safe, effective and affordable vaccine. Participation of sub-Saharan Africa in the conduct of HIV trials is crucial as this region still experiences high HIV incidences. We describe the experience of recruiting and...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4029747/ https://www.ncbi.nlm.nih.gov/pubmed/24321091 http://dx.doi.org/10.1186/1471-2458-13-1149 |
_version_ | 1782317271514873856 |
---|---|
author | Bakari, Muhammad Munseri, Patricia Francis, Joel Aris, Eric Moshiro, Candida Siyame, David Janabi, Mohamed Ngatoluwa, Mary Aboud, Said Lyamuya, Eligius Sandström, Eric Mhalu, Fred |
author_facet | Bakari, Muhammad Munseri, Patricia Francis, Joel Aris, Eric Moshiro, Candida Siyame, David Janabi, Mohamed Ngatoluwa, Mary Aboud, Said Lyamuya, Eligius Sandström, Eric Mhalu, Fred |
author_sort | Bakari, Muhammad |
collection | PubMed |
description | BACKGROUND: Eventual control of HIV/AIDS is believed to be ultimately dependent on a safe, effective and affordable vaccine. Participation of sub-Saharan Africa in the conduct of HIV trials is crucial as this region still experiences high HIV incidences. We describe the experience of recruiting and retaining volunteers in the first HIV vaccine trial (HIVIS03) in Tanzania. METHODS: In this trial enrolled volunteers from amongst Police Officers (POs) in Dar es Salaam were primed with HIV-1 DNA vaccine at months 0, 1 and 3; and boosted with HIV-1 MVA vaccine at months 9 and 21. A stepwise education provision/sensitization approach was employed to eventual recruitment. Having identified a “core” group of POs keen on HIV prevention activities, those interested to participate in the vaccine trial were invited for a first screening session that comprised of provision of detailed study information and medical evaluation. In the second screening session results of the initial assessment were provided and those eligible were assessed for willingness to participate (WTP). Those willing were consented and eventually randomized into the trial having met the eligibility criteria. Voluntary participation was emphasized throughout. RESULTS: Out of 408 POs who formed the core group, 364 (89.0%) attended the educational sessions. 263 out of 364 (72.2%) indicated willingness to participate in the HIV vaccine trial. 98% of those indicating WTP attended the pre-screening workshops. 220 (85.0%) indicated willingness to undergo first screening and 177 POs attended for initial screenings, of whom 162 (91.5%) underwent both clinical and laboratory screenings. 119 volunteers (73.5%) were eligible for the study. 79 were randomized into the trial, while 19 did not turn up, the major reason being partner/family advice. 60 volunteers including 15 females were recruited during a one-year period. All participated in the planned progress updates workshops. Retention into the schedule was: 98% for the 3 DNA/placebo vaccinations, while it was 83% and 73% for the first and second MVA/placebo vaccinations respectively. CONCLUSION: In this first HIV vaccine trial in Tanzania, we successfully recruited the volunteers and there was no significant loss to follow up. Close contact and updates on study progress facilitated the observed retention rates. TRIAL REGISTRATION NUMBERS: ISRCTN90053831 ISRNCT01132976 and ATMR2009040001075080 |
format | Online Article Text |
id | pubmed-4029747 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2013 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-40297472014-05-22 Experiences on recruitment and retention of volunteers in the first HIV vaccine trial in Dar es Salam, Tanzania - the phase I/II HIVIS 03 trial Bakari, Muhammad Munseri, Patricia Francis, Joel Aris, Eric Moshiro, Candida Siyame, David Janabi, Mohamed Ngatoluwa, Mary Aboud, Said Lyamuya, Eligius Sandström, Eric Mhalu, Fred BMC Public Health Research Article BACKGROUND: Eventual control of HIV/AIDS is believed to be ultimately dependent on a safe, effective and affordable vaccine. Participation of sub-Saharan Africa in the conduct of HIV trials is crucial as this region still experiences high HIV incidences. We describe the experience of recruiting and retaining volunteers in the first HIV vaccine trial (HIVIS03) in Tanzania. METHODS: In this trial enrolled volunteers from amongst Police Officers (POs) in Dar es Salaam were primed with HIV-1 DNA vaccine at months 0, 1 and 3; and boosted with HIV-1 MVA vaccine at months 9 and 21. A stepwise education provision/sensitization approach was employed to eventual recruitment. Having identified a “core” group of POs keen on HIV prevention activities, those interested to participate in the vaccine trial were invited for a first screening session that comprised of provision of detailed study information and medical evaluation. In the second screening session results of the initial assessment were provided and those eligible were assessed for willingness to participate (WTP). Those willing were consented and eventually randomized into the trial having met the eligibility criteria. Voluntary participation was emphasized throughout. RESULTS: Out of 408 POs who formed the core group, 364 (89.0%) attended the educational sessions. 263 out of 364 (72.2%) indicated willingness to participate in the HIV vaccine trial. 98% of those indicating WTP attended the pre-screening workshops. 220 (85.0%) indicated willingness to undergo first screening and 177 POs attended for initial screenings, of whom 162 (91.5%) underwent both clinical and laboratory screenings. 119 volunteers (73.5%) were eligible for the study. 79 were randomized into the trial, while 19 did not turn up, the major reason being partner/family advice. 60 volunteers including 15 females were recruited during a one-year period. All participated in the planned progress updates workshops. Retention into the schedule was: 98% for the 3 DNA/placebo vaccinations, while it was 83% and 73% for the first and second MVA/placebo vaccinations respectively. CONCLUSION: In this first HIV vaccine trial in Tanzania, we successfully recruited the volunteers and there was no significant loss to follow up. Close contact and updates on study progress facilitated the observed retention rates. TRIAL REGISTRATION NUMBERS: ISRCTN90053831 ISRNCT01132976 and ATMR2009040001075080 BioMed Central 2013-12-09 /pmc/articles/PMC4029747/ /pubmed/24321091 http://dx.doi.org/10.1186/1471-2458-13-1149 Text en Copyright © 2013 Bakari et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Article Bakari, Muhammad Munseri, Patricia Francis, Joel Aris, Eric Moshiro, Candida Siyame, David Janabi, Mohamed Ngatoluwa, Mary Aboud, Said Lyamuya, Eligius Sandström, Eric Mhalu, Fred Experiences on recruitment and retention of volunteers in the first HIV vaccine trial in Dar es Salam, Tanzania - the phase I/II HIVIS 03 trial |
title | Experiences on recruitment and retention of volunteers in the first HIV vaccine trial in Dar es Salam, Tanzania - the phase I/II HIVIS 03 trial |
title_full | Experiences on recruitment and retention of volunteers in the first HIV vaccine trial in Dar es Salam, Tanzania - the phase I/II HIVIS 03 trial |
title_fullStr | Experiences on recruitment and retention of volunteers in the first HIV vaccine trial in Dar es Salam, Tanzania - the phase I/II HIVIS 03 trial |
title_full_unstemmed | Experiences on recruitment and retention of volunteers in the first HIV vaccine trial in Dar es Salam, Tanzania - the phase I/II HIVIS 03 trial |
title_short | Experiences on recruitment and retention of volunteers in the first HIV vaccine trial in Dar es Salam, Tanzania - the phase I/II HIVIS 03 trial |
title_sort | experiences on recruitment and retention of volunteers in the first hiv vaccine trial in dar es salam, tanzania - the phase i/ii hivis 03 trial |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4029747/ https://www.ncbi.nlm.nih.gov/pubmed/24321091 http://dx.doi.org/10.1186/1471-2458-13-1149 |
work_keys_str_mv | AT bakarimuhammad experiencesonrecruitmentandretentionofvolunteersinthefirsthivvaccinetrialindaressalamtanzaniathephaseiiihivis03trial AT munseripatricia experiencesonrecruitmentandretentionofvolunteersinthefirsthivvaccinetrialindaressalamtanzaniathephaseiiihivis03trial AT francisjoel experiencesonrecruitmentandretentionofvolunteersinthefirsthivvaccinetrialindaressalamtanzaniathephaseiiihivis03trial AT ariseric experiencesonrecruitmentandretentionofvolunteersinthefirsthivvaccinetrialindaressalamtanzaniathephaseiiihivis03trial AT moshirocandida experiencesonrecruitmentandretentionofvolunteersinthefirsthivvaccinetrialindaressalamtanzaniathephaseiiihivis03trial AT siyamedavid experiencesonrecruitmentandretentionofvolunteersinthefirsthivvaccinetrialindaressalamtanzaniathephaseiiihivis03trial AT janabimohamed experiencesonrecruitmentandretentionofvolunteersinthefirsthivvaccinetrialindaressalamtanzaniathephaseiiihivis03trial AT ngatoluwamary experiencesonrecruitmentandretentionofvolunteersinthefirsthivvaccinetrialindaressalamtanzaniathephaseiiihivis03trial AT aboudsaid experiencesonrecruitmentandretentionofvolunteersinthefirsthivvaccinetrialindaressalamtanzaniathephaseiiihivis03trial AT lyamuyaeligius experiencesonrecruitmentandretentionofvolunteersinthefirsthivvaccinetrialindaressalamtanzaniathephaseiiihivis03trial AT sandstromeric experiencesonrecruitmentandretentionofvolunteersinthefirsthivvaccinetrialindaressalamtanzaniathephaseiiihivis03trial AT mhalufred experiencesonrecruitmentandretentionofvolunteersinthefirsthivvaccinetrialindaressalamtanzaniathephaseiiihivis03trial |